Maxim Group Highlights 3 Stem Cell Stocks To Consider And 1 To Avoid [View article]
Everyone do more homework.
Maxim could not be more biased for ASTM, PSTI and STEM. They had as recently as this past summer placed BUY recommendations on all three at higher prices than where they are currently trading. Furthermore, they raised 30 million for PSTI
Car Charging's Battle Against 'Range Anxiety' [View article]
The problem is that space is limited. Not everyone lives in a private house or has an indoor parking spot where they can install the charger or personal electric gas station thats why there wil have to be some sort of infrastructure along the way similar to todays regular gas stations. I was just wondering as to the scalability of the model and whether or not it would have to be government funded (which under the Obama administration has shown to be friendly to these types of ventures) or if private equity would be sufficient to get this sector moving...
Car Charging's Battle Against 'Range Anxiety' [View article]
great article. What about scaling up? Do you think that the US gov would have to be a partner in scaling up the infrastructure to a standard that would reinsure consumers regarding range anxiety or can it be done privately?
This $1 Biotech Stock Offers Limited Downside With Huge Reward Potential [View article]
Can you quickly address the concerns from the article you mentioned regarding the differences in Japans healthcare system and why their data shouldnt be used as a "rule of thumb" for this drug or for FDA decisions.
The Japanese data should be discounted because the country’s health system is different and because the reports aren’t detailed, panel member Julia Lewis, professor of medicine at Vanderbilt University Medical Center in Nashville, Tennessee, said during the meeting.
The company’s first trial examining Northera failed to show the drug worked, according to the FDA staff report. Chelsea Therapeutics then changed the endpoint that would measure success of another trial, which determined the treatment was effective. The endpoint changed from one set of questions asking patients about their ability to stand and walk to another set assessing a wider range of symptoms. The medicine would have shown same results even if Chelsea Therapeutics stuck with the first endpoint, the staff report said.
Maxim Group Highlights 3 Stem Cell Stocks To Consider And 1 To Avoid [View article]
Maxim could not be more biased for ASTM, PSTI and STEM. They had as recently as this past summer placed BUY recommendations on all three at higher prices than where they are currently trading. Furthermore, they raised 30 million for PSTI
The 'Local' Path To Mobile Marketing [View article]
Car Charging's Battle Against 'Range Anxiety' [View article]
Car Charging's Battle Against 'Range Anxiety' [View article]
This $1 Biotech Stock Offers Limited Downside With Huge Reward Potential [View article]
The Japanese data should be discounted because the country’s health system is different and because the reports aren’t detailed, panel member Julia Lewis, professor of medicine at Vanderbilt University Medical Center in Nashville, Tennessee, said during the meeting.
The company’s first trial examining Northera failed to show the drug worked, according to the FDA staff report. Chelsea Therapeutics then changed the endpoint that would measure success of another trial, which determined the treatment was effective. The endpoint changed from one set of questions asking patients about their ability to stand and walk to another set assessing a wider range of symptoms. The medicine would have shown same results even if Chelsea Therapeutics stuck with the first endpoint, the staff report said.
Colony Collapse Disorder As Part Of An Acquisition Strategy [View article]